242 related articles for article (PubMed ID: 27194387)
1. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.
Pennington LF; Tarchevskaya S; Brigger D; Sathiyamoorthy K; Graham MT; Nadeau KC; Eggel A; Jardetzky TS
Nat Commun; 2016 May; 7():11610. PubMed ID: 27194387
[TBL] [Abstract][Full Text] [Related]
2. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
Davies AM; Allan EG; Keeble AH; Delgado J; Cossins BP; Mitropoulou AN; Pang MOY; Ceska T; Beavil AJ; Craggs G; Westwood M; Henry AJ; McDonnell JM; Sutton BJ
J Biol Chem; 2017 Jun; 292(24):9975-9987. PubMed ID: 28438838
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
4. Structure of the omalizumab Fab.
Jensen RK; Plum M; Tjerrild L; Jakob T; Spillner E; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):419-26. PubMed ID: 25849503
[TBL] [Abstract][Full Text] [Related]
5. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Mitropoulou AN; Ceska T; Heads JT; Beavil AJ; Henry AJ; McDonnell JM; Sutton BJ; Davies AM
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):116-129. PubMed ID: 32133997
[TBL] [Abstract][Full Text] [Related]
6. Structural and Physical Basis for Anti-IgE Therapy.
Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
[TBL] [Abstract][Full Text] [Related]
7. Comparable actions of omalizumab on mast cells and basophils.
Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
9. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells.
Gomez G; Jogie-Brahim S; Shima M; Schwartz LB
J Immunol; 2007 Jul; 179(2):1353-61. PubMed ID: 17617628
[TBL] [Abstract][Full Text] [Related]
11. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab.
Zheng L; Li B; Qian W; Zhao L; Cao Z; Shi S; Gao J; Zhang D; Hou S; Dai J; Wang H; Guo Y
Biochem Biophys Res Commun; 2008 Oct; 375(4):619-22. PubMed ID: 18725193
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
Voskamp AL; Gillman A; Symons K; Sandrini A; Rolland JM; O'Hehir RE; Douglass JA
J Allergy Clin Immunol Pract; 2015; 3(2):192-9. PubMed ID: 25640470
[TBL] [Abstract][Full Text] [Related]
13. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.
Liu P; Pan Z; Gu C; Cao X; Liu X; Zhang J; Xiao Z; Wang X; Guo H; Ju D; Deng SJ
Front Immunol; 2020; 11():596908. PubMed ID: 33329588
[TBL] [Abstract][Full Text] [Related]
14. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
16. Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model.
Hsu CL; Shiung YY; Lin BL; Chang HY; Chang TW
Int Immunopharmacol; 2010 Apr; 10(4):533-9. PubMed ID: 20139035
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.
Garman SC; Wurzburg BA; Tarchevskaya SS; Kinet JP; Jardetzky TS
Nature; 2000 Jul; 406(6793):259-66. PubMed ID: 10917520
[TBL] [Abstract][Full Text] [Related]
19. A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition.
Hunt J; Keeble AH; Dale RE; Corbett MK; Beavil RL; Levitt J; Swann MJ; Suhling K; Ameer-Beg S; Sutton BJ; Beavil AJ
J Biol Chem; 2012 May; 287(21):17459-17470. PubMed ID: 22442150
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
